Registration for a live webinar on 'Innovations in antibiotic discovery: combating resistant infections' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Overview
- Inflammatory neuropathies
- Clinical spectrum
- Clinical presentation
- Spectra
- Acute inflammatory neuropathies
- Chronic inflammatory neuropathies
- Pattern in “typical” cases
- GBS versus CIDP
- Targets and mechanisms
- Potential mechanisms
- Potential effector mechanisms for nerve injury
- Methods to study or define pathological mechanisms
- Early evidence for neuropathy-associated anti-carbohydrate antibodies
- IgG antibodies to ganglioside in GBS
- Anti-ganglioside antibodies in the inflammatory neuropathies
- A true case of molecular mimicry?
- The node as a target for inflammatory neuropathy-associated antibodies
- Induced pluripotent SC derived sensory neurons
- Ganglioside antibody targeting nodal axolemma
- Calcium influx in sensory soma
- Calcium fluxes are a prelude to axonal degeneration
- Analysis of the electrophysiological effects of disialosyl antibodies and complement
- Reversible conduction failure vs. axonal degeneration
- GM1 & sulfatide antibodies may target glia directly
- Glial injury is followed by axolemmal nanoruptures, calcium influx, and secondary axonal degeneration
- Myelin proteins and T cells?
- The node of Ranvier
- Identification of specific antigens by immunoprecipitation
- Nodal/paranodal reactive antibodies in patients with inflammatory neuropathies
- Nodal/paranodal antibody syndromes: autoimmune nodopathies
- Nodal and paranodal antibody-associated neuropathies
- IgG4
- IgG4 does not activate complement
- Anti-contactin IgG4 antibodies have a (potentially) pathogenic “blocking” effect
- Anti-contactin IgG4 antibodies can disrupt nodal architecture
- Anti-neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo
- Contrasting pathological importance of monovalent versus bivalent paranodal antibodies
- CNTN1 immune complexes drive nephropathy?
- CNTN1 positive immune complexes are found in glomeruli
- Anti-CNTNI IgG3 induces acute conduction block and motor deficits in a passive transfer rat model
- panNF antibodies activate complement and disrupt myelin, nodal, and paranodal structure
- Established and upcoming therapies
- Established therapies
- Plasma exchange
- IVIg
- Rituximab
- Treatments and their effects on neuropathies
- Autoimmune nodopathies: treatment implications
- Rituximab appears effective
- Other approaches
- Imlifidase: an approach to eliminate pathogenic IgG
- 15-HMedIdeS-09: imlifidase in GBS patients
- FcRN inhibition
- ARGX-113-1802/Adhere
- Complement inhibition with a C5 convertase blocking mAb precent MAC pore deposition
- Eculizumab maintains nerve terminal integrity and prevents functional impairment
- Complement inhibition in GBS
- ANX005
- Protection of axonal and nodal integrity via overexpression of calpastatin
- Summary
Topics Covered
- Inflammatory neuropathies
- Acute inflammatory neuropathies
- Chronic inflammatory neuropathies
- Guillain-Barré syndrome (GBS)
- Chronic inflammatory demyelinating polyradicuoloneuropathy (CIDP)
- Anti-ganglioside antibodies
- GM1 and sulfatide antibodies
- The node of Ranvier
- IgG4
- CNTN1 immune complexes
- Established and upcoming therapies
Links
Series:
- The Immune System - Key Concepts and Questions
- Periodic Reports: Advances in Clinical Interventions and Research Platforms
Categories:
Therapeutic Areas:
Talk Citation
Rinaldi, S. (2025, April 30). Immunology of the peripheral nervous system: the inflammatory neuropathies [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 30, 2025, from https://doi.org/10.69645/RLTQ4692.Export Citation (RIS)
Publication History
- Published on April 30, 2025
Financial Disclosures
- Dr. Rinaldi has received honoraria for lectures given at the request of Excemed, Fresenius, CSL Behring, UCB, argenx, the Beijing Association of Holistic and Integrated Medicine, and the Irish Institute of Clinical Neuroscience. He has been a paid consultant for argenx, Annexon, Dianthus, Takeda and Hansa Biopharma. He runs a not-for-profit diagnostic testing service for nodal/paranodal antibodies.
Other Talks in the Series: The Immune System - Key Concepts and Questions
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. I'm Simon Rinaldi.
I'm an Associate
Professor of Neurology.
The lecture today is going to
be about the immunology of
the peripheral
nervous system with
a particular focus on
inflammatory neuropathies.
0:13
In this lecture,
I'm going to cover
the clinical spectrum of the
inflammatory neuropathies,
targets, and mechanisms
of these disorders in
an immunological sense and
also talk about established
and upcoming therapies.
0:25
Inflammatory neuropathies can
broadly be defined as a range of
disorders characterized by
immune-mediated damage
to peripheral nerves.
Within this broad definition,
there is a wide range of
different possibilities,
different disorders, and
different immune-mediated
mechanisms.
0:47
We think about the
clinical presentation of
neuropathies in general and
inflammatory neuropathies
in particular,
these can be associated
with a range of symptoms.
We can think of positive sensory
features such as tingling,
burning, and pain; and
negative sensory features
such as numbness,
loss of sensation, loss of
dexterity, and imbalance.
There can also be
motor involvement
with loss of strength and
the cranial nerves and
autonomic nervous system
can also be involved.
This also translates
into the range of
signs that can be seen
on clinical examination.
This includes weakness, which
can be distal or proximal,
wasting, cranial nerve
dysfunction, fasciculations,
reduced muscle tone,
suppression of
the deep tendon reflexes, and
evidence of sensory loss,
sensory ataxia, and
autonomic dysfunction.
1:31
The inflammatory neuropathies
can be considered
and placed on a range
of different spectra.
For example, some are
acute reaching nodes
within four weeks;
whereas, others have ongoing
progression and nerve injury
beyond eight weeks in
what we consider chronic.
Similarly, they can
be monophasic with
a single node and
improvement or they
can be relapsing
remitting, or
chronic progressive.
They may be focal,
multifocal, or generalized.
They may be pure motor,
pure sensory, or
sensory motor and they may
affect proximal or
distal muscles, or both.
Furthermore, the pathology can
affect the myelin
sheath and cause
demyelinating
neuropathies or primarily
targeted at the axon and
cause axonal neuropathies.
Hide